CLINICAL TRIALS PROFILE FOR KANAMYCIN
✉ Email this page to a colleague
All Clinical Trials for Kanamycin
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00004689 ↗ | Phase II Study of Amithiozone (Thiacetazone) for Patients With Mycobacterium Avium Complex Pulmonary Disease | Completed | National Jewish Health | Phase 2 | 1991-01-01 | OBJECTIVES: I. Determine the bacteriological activity of amithiozone against Mycobacterium avium complex (MAC) pulmonary disease. II. Define the ability of amithiozone to improve clinical outcomes in patients with MAC infection. III. Determine the safety and tolerance of amithiozone with chronic dosing in these patients. IV. Assess the contribution of clarithromycin, streptomycin, rifampin, ethambutol, kanamycin, and amithiozone in the treatment of pulmonary MAC infection. |
NCT00042289 ↗ | Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy | Completed | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 2003-03-01 | The purpose of this study is to evaluate the pharmacokinetics (PKs) of antiretroviral (ARV) and tuberculosis (TB) medications in pregnant women and their infants. (Pharmacokinetics are the various interactions between a drug and the body.) This study will also evaluate the PKs of certain ARVs in postpartum women before and after starting hormonal contraceptives. The PKs of these drugs will be evaluated by measuring the amount of medicine present in blood and/or vaginal secretions. | |
NCT00042289 ↗ | Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 2003-03-01 | The purpose of this study is to evaluate the pharmacokinetics (PKs) of antiretroviral (ARV) and tuberculosis (TB) medications in pregnant women and their infants. (Pharmacokinetics are the various interactions between a drug and the body.) This study will also evaluate the PKs of certain ARVs in postpartum women before and after starting hormonal contraceptives. The PKs of these drugs will be evaluated by measuring the amount of medicine present in blood and/or vaginal secretions. | |
NCT00579956 ↗ | A Randomized Double Blinded Comparison of Ceftazidime and Meropenem in Severe Melioidosis | Unknown status | Mahidol University | N/A | 2007-12-01 | Melioidosis, an infection caused by the bacterium Burkholderia pseudomallei, is a major cause of community-acquired septicaemia in northeast Thailand. Common manifestations include cavitating pneumonia, hepatic and splenic abscesses, and soft tissue and joint infections. Despite improvements in diagnostic procedures and treatment, the mortality of severe melioidosis remains unacceptably high - approximately 35% with currently used antibiotics (ceftazidime or co-amoxiclav). There is clear evidence that antibiotics can affect mortality; the use of ceftazidime rather than previous regimens (doxycycline + chloramphenicol + co-trimoxazole) led to a 50% reduction in mortality from 80% to 35%. However, the mortality in the first 48 hours has not been altered by any treatment regimen. A key question is whether alternative antibiotics could improve early outcome. The hypothesis tested is that meropenem is superior to ceftazidime in terms of mortality for the treatment of melioidosis. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Kanamycin
Condition Name
Clinical Trial Locations for Kanamycin
Trials by Country
Clinical Trial Progress for Kanamycin
Clinical Trial Phase
Clinical Trial Sponsors for Kanamycin
Sponsor Name
Sponsor Name for Kanamycin | |
Sponsor | Trials |
National Institute of Allergy and Infectious Diseases (NIAID) | 2 |
Janssen Infectious Diseases BVBA | 2 |
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 1 |
[disabled in preview] | 1 |
This preview shows a limited data set Subscribe for full access, or try a Trial |